Provided by Tiger Trade Technology Pte. Ltd.

Urogen Pharma Ltd.

46.16
-0.7000-1.49%
Post-market: 46.160.00000.00%19:30 EDT
Volume:849.69K
Turnover:39.39M
Market Cap:2.25B
PE:-23.43
High:47.05
Open:46.52
Low:45.27
Close:46.86
52wk High:50.81
52wk Low:15.86
Shares:48.68M
Float Shares:43.35M
Volume Ratio:0.67
T/O Rate:1.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9700
EPS(LYR):-3.1901
ROE:-1481.26%
ROA:-18.06%
PB:-16.97
PE(LYR):-14.47

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Tectonic Therapeutic (TECX) and Urogen Pharma (URGN)

TIPRANKS
·
May 18

UroGen Pharma Price Target Maintained With a $45.00/Share by HC Wainwright & Co.

Dow Jones
·
May 18

Analysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN) and CervoMed (CRVO)

TIPRANKS
·
May 18

UroGen Pharma reports month results from UTOPIA trial

TIPRANKS
·
May 15

UroGen Bladder Cancer Drug Achieves 94.5% Six-Month Response Duration

MT Newswires Live
·
May 15

UroGen Pharma Says ZUSDURI Shows Durable Disease-Free Outcomes at Three Years

MT Newswires Live
·
May 13

Urogen Pharma Ltd - Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial

Reuters
·
May 13

UroGen Pharma CMO Mark Schoenberg sells 10,000 shares for $300,000

Reuters
·
May 12

UroGen Pharma assumed with a Buy at Ladenburg

TIPRANKS
·
May 11

Stock Track | UroGen Pharma Soars 6.09% Intraday After H.C. Wainwright Raises Price Target to $45

Stock Track
·
May 11

UroGen Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 11

Urogen Pharma Ltd : H.c. Wainwright Raises Target Price to $45 From $40

THOMSON REUTERS
·
May 11

UroGen Pharma to present at Bank of America Health Care Conference 2026

Reuters
·
May 07

Stock Track | UroGen Pharma Soars 13.70% Intraday on Strong Q1 Earnings Beat and 152% Revenue Growth

Stock Track
·
May 07

Stock Track | UroGen Pharma Soars 5.67% in Pre-market on Strong Q1 Earnings Beat and 152% Revenue Growth

Stock Track
·
May 06

Earnings Flash (URGN) UroGen Pharma Posts Q1 Net Loss $0.47 a Share, vs. FactSet Est of $0.48 Loss

MT Newswires Live
·
May 06

UroGen Pharma Q1 revenue beats on ZUSDURI launch, net loss narrows

Reuters
·
May 06

UroGen Pharma Q1 EPS $(0.47) Beats $(0.48) Estimate, Sales $50.959M Beat $44.820M Estimate

Benzinga Earnings
·
May 06

UroGen Pharma publishes 2025 annual report

Reuters
·
May 01

UroGen Pharma to report first-quarter financial results, host conference call

Reuters
·
Apr 29